Research analysts covering IR-Med.
Recent press releases and 8-K filings for IRME.
IR-Med, Inc. Announces CEO Resignation and Private Placement
IRME
CEO Change
- IR-Med, Inc. completed a private placement offering on February 5, 2026, issuing an aggregate of 14,070,644 shares of common stock at $0.0031 per share and warrants to purchase up to an additional 7,035,322 shares at an exercise price of $0.03 per share, generating gross proceeds of $43,619.
- Five directors of the Company, including Oded Bashan, Yaniv Cohen, Yechiel Even, Ron Mayron, and Aharon Klein, participated in this private placement.
- Mr. Ran Ziskind resigned as Chief Executive Officer of IR-Med, Inc., effective February 3, 2026, due to disagreements with the Company's strategic direction, management approach, and employment matters.
4 hours ago
IR-Med, Inc. converts outstanding debt into common stock
IRME
- On September 5, 2025, IR-Med, Inc. entered into amendments to several loan agreements, converting $155,437 in outstanding debt, including accrued interest, into common stock.
- A total of 11,956,692 shares of the Company's common stock were issued at a fixed conversion price of $0.013 per share.
- The debt conversion involved lenders including Yaniv Cohen and Aharon Klein, both directors of the Company, and M2bwell LTD.
- The amended agreements included the 2015 Loan Agreement, 2017 Shareholders’ Loan Agreement, and 2018 Convertible Bridge Loan Agreement, with the debts under these agreements now fully satisfied and terminated.
Sep 11, 2025, 8:05 PM
Fintool News
In-depth analysis and coverage of IR-Med.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more